A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1902

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Dato-DXd
DRUG: Durvalumab
DRUG: Pembrolizumab
DRUG: Doxorubicin
DRUG: Epirubicin
DRUG: Cyclophosphamide
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Capecitabine
DRUG: Olaparib

Sponsor

AstraZeneca

Collaborators

[object Object]